Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | PREP | P48147 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | KDM1A | O60341 | 1/20 | 0.43 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | CTSL | P07711 | 1/20 | 0.43 |
| ▸ | CTSB | P07858 | 1/20 | 0.43 |
| ▸ | CTSS | P25774 | 1/20 | 0.43 |
| ▸ | CTSK | P43235 | 1/20 | 0.43 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.43 |
| ▸ | TPSD1 | Q9BZJ3 | 1/20 | 0.43 |
| ▸ | TPSG1 | Q9NRR2 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1660941 | 0.80 | HPGD (0.49) | ALDH1A1L3MBTL1 | |
| SCHEMBL17941734 | 0.79 | KMT2A (0.47) | KMT2A | |
| SCHEMBL9186562 | 0.78 | ALDH1A1 (0.44) | ALDH1A1SMN1; SMN2KMT2AL3MBTL1 | |
| SCHEMBL9684920 | 0.78 | CTSK (0.49) | PREPLMNACTSLCTSBCTSS | |
| SCHEMBL11065137 | 0.77 | HTT (0.51) | ALDH1A1PREPLMNASMN1; SMN2HTT | |
| SCHEMBL5257373 | 0.77 | CTSB (0.54) | CTSLCTSBCTSSCTSK | |
| SCHEMBL9115315 | 0.73 | ELANE (0.44) | ALDH1A1PREPGAA | |
| SCHEMBL5726699 | 0.72 | LMNA (0.61) | ALDH1A1LMNASMN1; SMN2HTTCTSL | |
| SCHEMBL126974 | 0.72 | HTT (0.66) | ALDH1A1LMNASMN1; SMN2HTTCTSL | |
| SCHEMBL6741072 | 0.72 | LMNA (0.65) | ALDH1A1LMNASMN1; SMN2HTTKDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7863304-B2 | Analogs of glycyl-prolyl-glutamate | NEUREN PHARMACEUTICALS LIMITED (NZ) | 2011-01-04 | — | — | US | disclosed |
| EP-1888618-A4 | ANALOGS OF GLYCYL-PROLYL-GLUTAMATE | NEUREN PHARMACEUTICALS LTD (NZ) | 2009-07-15 | — | — | EP | disclosed |
| US-20080145335-A1 | Analogs of Glycyl-Prolyl-Glutamate | NEUREN PHARMACEUTICALS LIMITED (NZ) | 2008-06-19 | — | — | US | disclosed |
| EP-1888618-A2 | ANALOGS OF GLYCYL-PROLYL-GLUTAMATE | Neuren Pharmaceuticals Limited (NZ) | 2008-02-20 | — | — | EP | disclosed |
| EP-1500657-B1 | Substituted pyrazoles as P38 kinase inhibitors | SEARLE LLC (US) | 2007-09-19 | — | — | EP | disclosed |
| US-20070078146-A1 | Antiinflamamtory agents; antiarthritic agents; inflammatory bowel disorders; multiple sclerosis; asthma | PHARMACIA CORPORATION | 2007-04-05 | — | — | US | disclosed |
| US-7153959-B2 | treatment of tumor necrosis factor mediated disorders; asthma; inflammatory bowel disease; arthritis | PHARMACIA CORPORATION (US) | 2006-12-26 | — | — | US | disclosed |
| WO-2006127702-A2 | ANALOGS OF GLYCYL-PROLYL-GLUTAMATE | NEUREN PHARMACEUTICALS LIMITED (NZ) | 2006-11-30 | — | — | WO | disclosed |
| US-7071198-B1 | Antiinflamamtory agents; antiarthritic agents; inflammatory bowel disorders; multiple sclerosis; asthma | PHARMACIA CORPORATION (US) | 2006-07-04 | — | — | US | disclosed |
| US-6979686-B1 | Substituted pyrazoles as p38 kinase inhibitors | PHARMACIA CORPORATION (US) | 2005-12-27 | — | — | US | disclosed |
| US-4226979-A | ANTIBIOTICS, BACTERICIDES | ABBOTT LABORATORIES (US) | 1980-10-07 | — | — | US | disclosed |
| US-4219644-A | Fortimicins AH and AI | ABBOTT LABORATORIES (US) | 1980-08-26 | — | — | US | disclosed |
| US-4219642-A | Fortimicin AO | ABBOTT LABORATORIES (US) | 1980-08-26 | — | — | US | disclosed |
| US-4216210-A | Fortimicins AM and AP derivatives | ABBOTT LABORATORIES (US) | 1980-08-05 | — | — | US | disclosed |
| US-4214079-A | 4-N, 2'-N and 4,2'-Di-N-fortimicin AL derivatives | ABBOTT LABORATORIES (US) | 1980-07-22 | — | — | US | disclosed |
| US-4214078-A | Fortimicin AL | ABBOTT LABORATORIES (US) | 1980-07-22 | — | — | US | disclosed |
| US-4213974-A | ANTIBACTERIAL | ABBOTT LABORATORIES (US) | 1980-07-22 | — | — | US | disclosed |
| US-4213971-A | BACTERICIDES | ABBOTT LABORATORIES (US) | 1980-07-22 | — | — | US | disclosed |
| US-4213972-A | BACTERICIDES | ABBOTT LABORATORIES (US) | 1980-07-22 | — | — | US | disclosed |
| US-4183920-A | ANTIBIOTICS | ABBOTT LABORATORIES (US) | 1980-01-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080145335-A1 | Analogs of Glycyl-Prolyl-Glutamate | GLS, GLUL, HIF1A | ALDH1A1 574/4885PREP 24/4885LMNA 2571/4885 |
| US-20070078146-A1 | Antiinflamamtory agents; antiarthritic agents; inflammatory bowel disorders; multiple sclerosis; asthma | MAPK1, MAPK3, MAPK4 | ALDH1A1 1079/4885PREP 1023/4885LMNA 4386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.